Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2025 ,inter alia, to consider and approve Intimation of Board meeting
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma has informed the exchanges that its Board of Directors will meet on Wednesday, November 5, 2025, to consider and approve the Standalone and Consolidated Unaudited Financial Results for the second quarter and half year ended September 30, 2025 (Q2/H1 FY26). The company also confirmed that the trading window for dealing in its shares will remain closed until November 7, 2025 (48 hours after results are declared), and will reopen on November 8, 2025. This is a routine compliance filing under SEBI's Listing Regulations ahead of the Q2 earnings announcement.
No immediate price impact expected from the intimation itself. Investors should watch November 5, 2025 for the actual Q2 FY26 results, which will be a key catalyst. The closed trading window until November 7 signals that insiders are restricted from trading, suggesting material disclosures are imminent.